What is HC Wainwright’s Forecast for MediWound Q1 Earnings?

MediWound Ltd. (NASDAQ:MDWD) – Stock analysts at HC Wainwright decreased their Q1 2025 EPS estimates for MediWound in a report released on Thursday, March 20th. HC Wainwright analyst S. Ramakanth now expects that the biopharmaceutical company will post earnings per share of ($0.61) for the quarter, down from their previous forecast of ($0.56). HC Wainwright currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for MediWound’s current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for MediWound’s Q2 2025 earnings at ($0.66) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.71) EPS, FY2026 earnings at ($1.98) EPS, FY2027 earnings at ($1.16) EPS and FY2028 earnings at $0.80 EPS.

Other research analysts also recently issued research reports about the company. Craig Hallum initiated coverage on MediWound in a research note on Friday, February 28th. They issued a “buy” rating and a $39.00 target price for the company. StockNews.com raised shares of MediWound to a “sell” rating in a report on Friday, March 21st.

MediWound Price Performance

MediWound stock opened at $16.66 on Monday. MediWound has a one year low of $12.78 and a one year high of $24.00. The firm has a market capitalization of $179.81 million, a P/E ratio of -5.74 and a beta of 0.82. The business has a fifty day moving average price of $18.08 and a 200-day moving average price of $17.59.

MediWound (NASDAQ:MDWD) last released its quarterly earnings data on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.23. The business had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.79 million. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same period in the previous year, the business earned ($0.19) EPS.

Institutional Investors Weigh In On MediWound

Institutional investors and hedge funds have recently made changes to their positions in the business. Rhumbline Advisers increased its stake in MediWound by 7.3% in the 4th quarter. Rhumbline Advisers now owns 10,835 shares of the biopharmaceutical company’s stock worth $193,000 after acquiring an additional 739 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of MediWound by 154.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,916 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,162 shares during the last quarter. Barclays PLC raised its stake in MediWound by 11.2% in the fourth quarter. Barclays PLC now owns 12,412 shares of the biopharmaceutical company’s stock valued at $221,000 after purchasing an additional 1,249 shares in the last quarter. R Squared Ltd bought a new stake in MediWound during the fourth quarter valued at approximately $32,000. Finally, Bank of America Corp DE grew its stake in MediWound by 38.0% in the 4th quarter. Bank of America Corp DE now owns 7,915 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 2,178 shares in the last quarter. Hedge funds and other institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.